TRVI (Trevi Therapeutics Inc) may reap gains as insiders became active recently

NUE

In a filing, Trevi Therapeutics Inc revealed its Chief Scientific Officer SCIASCIA THOMAS unloaded Company’s shares for reported $17365.0 on Mar 25 ’25. In the deal valued at $6.60 per share,2,631 shares were sold. As a result of this transaction, SCIASCIA THOMAS now holds 221,373 shares worth roughly $1.3 million.

Then, GOOD JENNIFER L sold 5,263 shares, generating $34,625 in total proceeds. Upon selling the shares at $6.58, the President & CEO now owns 213,313 shares.

Before that, GOOD JENNIFER L bought 5,263 shares. Trevi Therapeutics Inc shares valued at $34,625 were divested by the Officer at a price of $6.58 per share.

Cantor Fitzgerald initiated its Trevi Therapeutics Inc [TRVI] rating to an Overweight in a research note published on July 01, 2025; the price target was $25. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late May with a ‘”a Buy”‘ rating. Raymond James also remained covering TRVI and has increased its forecast on March 10, 2025 with a “Strong buy” recommendation from previously “an Outperform” rating. Needham maintained its rating on March 10, 2025. It rated TRVI as “a Buy”.

Price Performance Review of TRVI

On Tuesday, Trevi Therapeutics Inc [NASDAQ:TRVI] saw its stock fall -1.60% to $5.86. Over the last five days, the stock has gained 7.04%. Trevi Therapeutics Inc shares have risen nearly 119.29% since the year began. Nevertheless, the stocks have risen 42.11% over the past one year. While a 52-week high of $7.48 was reached on 06/02/25, a 52-week low of $2.36 was recorded on 01/22/25.

Levels Of Support And Resistance For TRVI Stock

The 24-hour chart illustrates a support level at 5.73, which if violated will result in even more drops to 5.61. On the upside, there is a resistance level at 6.03. A further resistance level may holdings at 6.21.

How much short interest is there in Trevi Therapeutics Inc?

A steep rise in short interest was recorded in Trevi Therapeutics Inc stocks on 2025-06-13, growing by 0.76 million shares to a total of 7.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.87 million shares. There was a rise of 9.93%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on December 12, 2024 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $7.50.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.